Theravance Biopharma (TBPH) Total Debt (2018 - 2022)

Theravance Biopharma (TBPH) has 5 years of Total Debt data on file, last reported at $396.1 million in Q2 2022.

• Total Debt for Q2 2022 came in at $396.1 million, up 3.69% year-over-year; the trailing twelve-month figure through Jun 2022 was $396.1 million (up 3.69% YoY), and the FY2021 annual result was $388.3 million, down 1.0% from the prior year.
• Total Debt improved to $396.1 million in Q2 2022 per TBPH's latest filing, from $393.2 million in the prior quarter.
• Over five years, Total Debt peaked at $396.1 million in Q2 2022 and troughed at $229.2 million in Q4 2019.
• A 5-year average of $334.0 million and a median of $382.0 million in 2021 frame the typical range for Total Debt.
• The sharpest annual moves came in 2020 and 2021: Total Debt soared 71.16% in 2020, then retreated 1.0% in 2021.
• A 5-year view of Total Debt shows it stood at $229.5 million in 2018, then dropped by 0.17% to $229.2 million in 2019, then soared by 71.16% to $392.2 million in 2020, then declined by 1.0% to $388.3 million in 2021, then gained by 2.02% to $396.1 million in 2022.
• Business Quant data shows TBPH's Total Debt at $396.1 million in Q2 2022, $393.2 million in Q1 2022, and $388.3 million in Q4 2021.